knowledge -WSS

knowledge

author：focus 2025-09-29 22:47:18 - browse：8

LONDON — AstraZeneca said Friday an experimental drug tamped down the progression of a certain type of breast cancer in a Phase 3 trial, a win for the company after the same drug produced underwhelming results in a lung cancer trial over the summer.

The drug, called datopotamab deruxtecan or Dato-DXd for short, succeeded on one of its primary endpoints of improving progression-free survival compared to chemotherapy in certain breast cancer patients who had previously been treated with other therapies.

AstraZeneca, which is developing Dato-DXd with partner Daiichi Sankyo, said that the data for the other primary endpoint of overall survival were not “mature” as of this interim analysis, but that there was a positive trend. The trial is continuing.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Why palliative psychiatry is worth discussing

focus

WSS

Second xenotransplant done with gene

Senate HELP committee spars over health care workforce policies

How AI helped researchers track recovery from depression

CDC advisers recommend seasonal use of Pfizer RSV shot

Medical student insurance fails on mental health care coverage

Biotech stock slump in 2023: awaiting the turnaround

hotspot

knowledge

knowledge

Dobbs anniversary: the lost opportunity of abortion as health care

Medical student insurance fails on mental health care coverage

Virginia high school admissions case could be legal follow

R1 RCM gets $5.8 billion buyout offer from private equity firm

Malaria cases in Florida and Texas: Here’s what you need to know

CDC advisers recommend seasonal use of Pfizer RSV shot

Trump demands the U.S. pay no more for drugs than other countries … again

CommonSpirit Health keeps growing, even as it loses money

Continuity nursing helped my family in our darkest PICU moments

The Harvard botanist who searched for psychedelics in the Amazon

focus

FDA panel to weigh approval of NurOwn, controversial ALS drug

Alabama IVF ruling threatens families facing fatal genetic disease

New documents shed light on MD Anderson Cancer Institute feud

Lasker Awards 2023: Winners in biomedical research

Intarcia’s device

Medical student insurance fails on mental health care coverage

focus

focus

focus

leisure time